Dr Howard J Broder, MD | |
2865 Siena Heights Dr, Suite 331, Henderson, NV 89052-4167 | |
(702) 731-8224 | |
(702) 990-8757 |
Full Name | Dr Howard J Broder |
---|---|
Gender | Male |
Speciality | Interventional Cardiology |
Experience | 22 Years |
Location | 2865 Siena Heights Dr, Henderson, Nevada |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1336361500 | NPI | - | NPPES |
1336361500 | Medicaid | NV |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | 13134 (Nevada) | Secondary |
207RI0011X | Internal Medicine - Interventional Cardiology | 13134 (Nevada) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Saint Rose Dominican Hospitals - Siena Campus | Henderson, NV | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Intermountain Medical Holdings Nevada Inc | 7416054622 | 286 |
News Archive
Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation, a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.
Smoking not only causes bladder cancer-it also affects its course, in that people who smoke more have greater likelihood of developing more aggressive and deadly disease. That is one of the conclusions of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities.
› Verified 5 days ago
Entity Name | Healthcare Partners Medical Group Coats Ltd |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1487631917 PECOS PAC ID: 5991866303 Enrollment ID: O20100113000898 |
News Archive
Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation, a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.
Smoking not only causes bladder cancer-it also affects its course, in that people who smoke more have greater likelihood of developing more aggressive and deadly disease. That is one of the conclusions of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities.
› Verified 5 days ago
Entity Name | Intermountain Medical Holdings Nevada Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1245997279 PECOS PAC ID: 7416054622 Enrollment ID: O20220214001765 |
News Archive
Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation, a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.
Smoking not only causes bladder cancer-it also affects its course, in that people who smoke more have greater likelihood of developing more aggressive and deadly disease. That is one of the conclusions of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Howard J Broder, MD 6355 S Buffalo Dr Fl 3, Las Vegas, NV 89113-2133 Ph: (702) 216-3346 | Dr Howard J Broder, MD 2865 Siena Heights Dr, Suite 331, Henderson, NV 89052-4167 Ph: (702) 731-8224 |
News Archive
Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation, a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.
Smoking not only causes bladder cancer-it also affects its course, in that people who smoke more have greater likelihood of developing more aggressive and deadly disease. That is one of the conclusions of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities.
› Verified 5 days ago
James B Gabroy, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1535 West Warm Spring Road, Suite 135, Henderson, NV 89014 Phone: 702-450-3385 Fax: 702-898-1699 | |
Dr. Poupak Ziaei, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2641 W Horizon Ridge Pkwy Ste 100, Henderson, NV 89052 Phone: 702-616-0091 Fax: 702-616-2329 | |
Dr. Jeannette Nee, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2865 Siena Heights Dr, Suite 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 | |
Wen Liang, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2621 W Horizon Ridge Pkwy, Suite 150, Henderson, NV 89052 Phone: 702-837-6368 Fax: 702-837-0685 | |
Randy James Ip, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2865 Siena Heights Dr Ste 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 | |
Linda Lou Johnson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1501 W Sunset Rd, Henderson, NV 89014 Phone: 725-269-7001 Fax: 725-269-7003 | |
Dr. Daejoon Anh, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2865 Siena Heights Dr Ste 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 |